Publication: A single dose of LSD does not alter gene expression of the serotonin 2A receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects
A single dose of LSD does not alter gene expression of the serotonin 2A receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects
Date
Date
Date
Citations
Dolder, P. C., Grünblatt, E., Müller, F., Borgwardt, S. J., & Liechti, M. E. (2017). A single dose of LSD does not alter gene expression of the serotonin 2A receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects. Frontiers in Pharmacology, 8, 423. https://doi.org/10.3389/fphar.2017.00423
Abstract
Abstract
Abstract
Rationale: Renewed interest has been seen in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation. In rats, daily LSD administration for 4 days decreased frontal cortex 5-HT2A receptor binding. Additionally, a single dose of LSD acutely increased expression of the early growth response genes EGR1 and EGR2 in rat and mouse brains through 5-HT2A receptor stimulation. No human data on the
Additional indexing
Creators (Authors)
- Dolder, Patrick C
- Grünblatt, Edna
- Müller, Felix
- Borgwardt, Stefan J
- Liechti, Matthias E
Volume
Volume
Volume
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Citations
Dolder, P. C., Grünblatt, E., Müller, F., Borgwardt, S. J., & Liechti, M. E. (2017). A single dose of LSD does not alter gene expression of the serotonin 2A receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects. Frontiers in Pharmacology, 8, 423. https://doi.org/10.3389/fphar.2017.00423
